Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non‐dialysis CKD: An observational study. Issue 4 (14th June 2021)
- Record Type:
- Journal Article
- Title:
- Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non‐dialysis CKD: An observational study. Issue 4 (14th June 2021)
- Main Title:
- Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non‐dialysis CKD: An observational study
- Authors:
- Emrich, Insa E.
Heine, Gunnar H.
Schulze, P. Christian
Rogacev, Kyrill S.
Fliser, Danilo
Wagenpfeil, Stefan
Böhm, Michael
Lütjohann, Dieter
Weingärtner, Oliver - Abstract:
- Abstract: In dialysis patients, cholesterol‐lowering therapy with statins is less effective than in other high‐risk patients. This may be explained by a shift from cholesterol synthesis toward cholesterol absorption. In line, markers of cholesterol absorption—such as campesterol—better predict atherosclerotic cardiovascular events than markers of cholesterol synthesis—such as lathosterol—in dialysis patients. To test the association between markers of cholesterol absorption such as campesterol—and markers of cholesterol synthesis—such as lathosterol—against cardiovascular events in non‐dialysis CKD patients. Altogether 251 patients not on lipid‐lowering agents were followed annually for the composite endpoint atherosclerotic cardiovascular disease (ASCVD) and all‐cause death. During follow‐up of 5.2 ± 2.1 years, 61 participants reached the primary endpoint atherosclerotic cardiovascular disease/all‐cause death [ASCVD/D], 47 participants suffered from ASCVD, and 46 participants died. In univariate Cox regression analysis, campesterol/lathosterol ratio did not significantly predict ASCVD/D (HR 0.643; 0.358–1.155; 3rd vs. 1st tertile), all‐cause death (HR 1.309; 0.604–2.838; 3rd vs. 1st tertile) nor ASCVD (HR 0.589; 0.311–1.118; 3rd vs. 1st tertile). We did not observe a shift from cholesterol synthesis to cholesterol absorption across the spectrum of non‐dialysis CKD. Campesterol/lathosterol ratio did not predict future ASCVD or all‐cause death in non‐dialysis CKD. Abstract :Abstract: In dialysis patients, cholesterol‐lowering therapy with statins is less effective than in other high‐risk patients. This may be explained by a shift from cholesterol synthesis toward cholesterol absorption. In line, markers of cholesterol absorption—such as campesterol—better predict atherosclerotic cardiovascular events than markers of cholesterol synthesis—such as lathosterol—in dialysis patients. To test the association between markers of cholesterol absorption such as campesterol—and markers of cholesterol synthesis—such as lathosterol—against cardiovascular events in non‐dialysis CKD patients. Altogether 251 patients not on lipid‐lowering agents were followed annually for the composite endpoint atherosclerotic cardiovascular disease (ASCVD) and all‐cause death. During follow‐up of 5.2 ± 2.1 years, 61 participants reached the primary endpoint atherosclerotic cardiovascular disease/all‐cause death [ASCVD/D], 47 participants suffered from ASCVD, and 46 participants died. In univariate Cox regression analysis, campesterol/lathosterol ratio did not significantly predict ASCVD/D (HR 0.643; 0.358–1.155; 3rd vs. 1st tertile), all‐cause death (HR 1.309; 0.604–2.838; 3rd vs. 1st tertile) nor ASCVD (HR 0.589; 0.311–1.118; 3rd vs. 1st tertile). We did not observe a shift from cholesterol synthesis to cholesterol absorption across the spectrum of non‐dialysis CKD. Campesterol/lathosterol ratio did not predict future ASCVD or all‐cause death in non‐dialysis CKD. Abstract : This study tested the association between markers of cholesterol metabolism (campesterol‐to‐lathosterol) against atherosclerotic cardiovascular disease and all‐cause death in non‐dialysis CKD patients. … (more)
- Is Part Of:
- Pharmacology research & perspectives. Volume 9:Issue 4(2021)
- Journal:
- Pharmacology research & perspectives
- Issue:
- Volume 9:Issue 4(2021)
- Issue Display:
- Volume 9, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 9
- Issue:
- 4
- Issue Sort Value:
- 2021-0009-0004-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-06-14
- Subjects:
- cardiovascular disease -- cholesterol absorption -- cholesterol synthesis -- renal impairment
Pharmacology -- Periodicals
Drug development -- Periodicals
615.105 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2052-1707 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/prp2.801 ↗
- Languages:
- English
- ISSNs:
- 2052-1707
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24387.xml